Kyowa Hakko And Aussie Firm Arana To Co-Develop Anti-Cancer Drug
This article was originally published in PharmAsia News
Japanese biotech firm Kyowa Hakko announced April 24 an agreement with the Australian firm Arana Therapeutic to co-develop a new anti-cancer drug ART104 for colorectal cancer. Kyowa Hakko plans to use its own antibody technologies to enhance drug candidate, which the companies hope enters the clinical trial phase by 2010. Arana will receive a one time payment of $4 million and up to $4 million in milestone payments. Kyowa Hakko has an option to develop and commercialize the product in some Asian markets such as Japan, South Korea, Taiwan and China. Arana will receive royalties on these sales. (Click here for more - Japanese language
You may also be interested in...
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.